𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial

✍ Scribed by O. Rascol; J. Bronzova; R.A. Hauser; A.E. Lang; C. Sampaio; A. Theeuwes; S.V. van de Witte

Book ID
116821149
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
436 KB
Volume
18
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Randomized trial of tolcapone versus per
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),

A multicenter double-blind placebo-contr
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
✍ Dr. C. W. Olanow; S. Fahn; M. Muenter; H. Klawans; H. Hurtig; M. Stern; I. Shoul 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 778 KB

## Abstract Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnific